Price (delayed)
$6.92
Market cap
$135.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.26
Enterprise value
$126.52M
We are a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). We ...
Highlights
The EPS has surged by 81% year-on-year and by 79% since the previous quarter
Actuate Therapeutics's quick ratio has soared by 128% YoY but it has decreased by 38% from the previous quarter
Actuate Therapeutics's equity has soared by 100% YoY but it has plunged by 98% from the previous quarter
Key stats
What are the main financial stats of ACTU
MarketValuationsEarnings
Shares outstanding
19.53M
Market cap
$135.16M
Enterprise value
$126.52M
Price to earnings (P/E)
N/A
Price to book (P/B)
1,297.28
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$25.16M
Net income
-$27.29M
EBIT
-$27.27M
EBITDA
-$27.27M
Free cash flow
-$21.84M
Per shareBalance sheetLiquidity
EPS
-$3.26
EPS diluted
-$3.26
Free cash flow per share
-$2.61
Book value per share
$0.01
Revenue per share
$0
TBVPS
$1.11
Total assets
$9.32M
Total liabilities
$9.21M
Debt
$0
Equity
$104,186
Working capital
$405,397
Debt to equity
0
Current ratio
1.05
Quick ratio
0.98
Net debt/EBITDA
0.32
MarginsEfficiencyDividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-389.6%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-5,284.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACTU stock price
How has the Actuate Therapeutics stock price performed over time
Intraday
0.14%
1 week
-8.71%
1 month
6.3%
1 year
N/A
YTD
-13.07%
QTD
2.22%
Financial performance
How have Actuate Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$25.16M
Net income
-$27.29M
Gross margin
N/A
Net margin
N/A
ACTU financials
ACTU's net income is down by 10% YoY but it is up by 4.1% from the previous quarter
Actuate Therapeutics's operating income has increased by 4% from the previous quarter
Growth
What is Actuate Therapeutics's growth rate over time
ACTU growth chart
Valuation
What is Actuate Therapeutics stock price valuation
P/E
N/A
P/B
1,297.28
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Price to earnings (P/E)
The EPS has surged by 81% year-on-year and by 79% since the previous quarter
Price to book (P/B)
Actuate Therapeutics's equity has soared by 100% YoY but it has plunged by 98% from the previous quarter
Price to sales (P/S)
Efficiency
How efficient is Actuate Therapeutics business performance
Actuate Therapeutics's ROA has plunged by 85% YoY but it has increased by 26% from the previous quarter
Dividends
What is ACTU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACTU.
Financial health
How did Actuate Therapeutics financials performed over time
Assets vs liabilities
The current ratio has soared by 144% YoY but it has contracted by 38% from the previous quarter
Actuate Therapeutics's quick ratio has soared by 128% YoY but it has decreased by 38% from the previous quarter
Debt vs equity
ACTU's debt is 100% lower than its equity
Actuate Therapeutics's equity has soared by 100% YoY but it has plunged by 98% from the previous quarter
Balance sheet
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from 
and Sharadar.